Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II

NCT06467084 is registered in ClinicalTrials.gov with KalVista Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT06467084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06467084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2024
Completion date
January 15, 2026
Enrollment
36 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema